Allovir, Inc. financial data

Symbol
ALVR on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
1100 Winter Street, Waltham, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
ViraCyte, Inc. (to 10/2/2018)
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.46K % +77.8%
Debt-to-equity 15.9 % -36%
Return On Equity -79 % +1.52%
Return On Assets -68.1 % -6.09%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 116M shares +1.29%
Common Stock, Shares, Outstanding 115M shares +1.29%
Entity Public Float 265M USD +84.9%
Common Stock, Value, Issued 11K USD 0%
Weighted Average Number of Shares Outstanding, Basic 115M shares +1.32%
Weighted Average Number of Shares Outstanding, Diluted 115M shares +1.32%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 79.8M USD -35.6%
General and Administrative Expense 34.2M USD -31.4%
Operating Income (Loss) -108M USD +39.2%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -44.3M USD -5.23%
Income Tax Expense (Benefit) -126K USD +69.6%
Net Income (Loss) Attributable to Parent -100M USD +40.7%
Earnings Per Share, Basic -0.87 USD/shares +46.6%
Earnings Per Share, Diluted -0.87 USD/shares +46.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 117M USD +22.2%
Cash, Cash Equivalents, and Short-term Investments 122M USD -42.9%
Assets, Current 123M USD -44.3%
Property, Plant and Equipment, Net 673K USD -28.6%
Operating Lease, Right-of-Use Asset 495K USD -98.2%
Other Assets, Noncurrent 122K USD -80.1%
Assets 123M USD -50.7%
Accounts Payable, Current 51K USD -98.7%
Accrued Liabilities, Current 1.36M USD -91.5%
Liabilities, Current 1.41M USD -95.7%
Operating Lease, Liability, Noncurrent 8.34M USD -63.8%
Liabilities 1.41M USD -97.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax -134K USD +33%
Retained Earnings (Accumulated Deficit) -697M USD -16.8%
Stockholders' Equity Attributable to Parent 121M USD -38%
Liabilities and Equity 123M USD -50.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -44.4M USD -38.2%
Net Cash Provided by (Used in) Investing Activities 40M USD -4.13%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 115M shares +1.29%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -4.38M USD -146%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 117M USD +21.1%
Deferred Tax Assets, Valuation Allowance 181M USD +120%
Deferred Tax Assets, Gross 181M USD +102%
Operating Lease, Liability 9M USD -71.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -100M USD +40.6%
Lessee, Operating Lease, Liability, to be Paid 11M USD -69.7%
Property, Plant and Equipment, Gross 1.92M USD -0.83%
Operating Lease, Liability, Current 667K USD -92.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.3M USD +2.14%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.22M USD -72.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure -16.2%
Deferred Income Tax Expense (Benefit) 0 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.19M USD -39.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.38M USD +2.06%
Deferred Tax Assets, Operating Loss Carryforwards 54.1M USD +477%
Preferred Stock, Shares Issued 0 shares
Current Income Tax Expense (Benefit) -265K USD -126%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.46M USD +2.04%
Operating Lease, Payments 16.1M USD +121%
Additional Paid in Capital 818M USD +3.27%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 86K USD -81.5%
Deferred Tax Assets, Net of Valuation Allowance 500K USD -93.3%
Share-based Payment Arrangement, Expense 25.9M USD -35%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%